Do anti-VEGFs used in the ophthalmic clinic cause Müller glial cell stress?

Clinics (Sao Paulo)

Department of Ophthalmology, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, SP, Brazil.

Published: January 2023

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883173PMC
http://dx.doi.org/10.1016/j.clinsp.2022.100161DOI Listing

Publication Analysis

Top Keywords

anti-vegfs ophthalmic
4
ophthalmic clinic
4
clinic müller
4
müller glial
4
glial cell
4
cell stress?
4
anti-vegfs
1
clinic
1
müller
1
glial
1

Similar Publications

Purpose: To report an incidence of procedure-related complications in preterm infants with retinopathy of prematurity (ROP) treated with intravitreal anti-VEGFs injection in both eyes on the same day.

Design: Retrospective, multicenter case series.

Subjects: Preterm infants with ROP treated with anti-VEGF bilaterally on the same day.

View Article and Find Full Text PDF

Patient-Centered Economic Burden of Diabetic Macular Edema: Retrospective Cohort Study.

JMIR Public Health Surveill

October 2024

Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea.

Article Synopsis
  • Diabetic macular edema (DME) is a serious eye condition that can cause blindness and costs a lot of money to treat with special drugs.
  • A study looked at three years of medical costs for patients with DME and compared them to patients with diabetes but without DME.
  • The results showed that patients with DME spent more than double on medical costs compared to those without DME.
View Article and Find Full Text PDF

Objective: Age-related macular degeneration (AMD) is the main cause of severe vision loss globally. Neovascular AMD (nAMD) is an advanced stage of AMD treated with anti-vascular endothelial growth factors (anti-VEGFs). Although anti-VEGF treatment is effective, the frequent intravitreal injections place a burden on patients, (in)formal caregivers, and clinics.

View Article and Find Full Text PDF

Objective: The efficacy and safety of propranolol for retinopathy of prematurity (ROP) remain under debate. This network meta-analysis (NMA) focuses on whether a ranking may be established for different dose levels of propranolol as treatment of ROP in terms of stage progression as the primary outcome, with appearance of plus disease and need for anti-vascular endothelial growth factors (anti-VEGFs) or laser therapy as secondary endpoints.

Methods: Fourteen studies (10 randomised controlled trials, three single-arm trials and one retrospective observational study) of 474 patients treated with oral or ocular propranolol were retrieved from databases up to April 2024.

View Article and Find Full Text PDF

Italian Patient Satisfaction with wAMD Management: SWAN Study Results.

Clin Ophthalmol

August 2024

Eye Clinic, Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan, Milan, Italy.

Purpose: Limited data is available on treatment satisfaction with the management of wet age-related macular degeneration (wAMD) among patients in Italy. In this cross-sectional real-world study, treatment satisfaction with anti-vascular endothelial growth factor (anti-VEGFs) was assessed in patients with wAMD in Italy.

Patients And Methods: This was a non-interventional, cross-sectional survey involving patients with wAMD receiving anti-VEGFs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!